Meet Our Executive Team
Chief Executive Officer
Mr. Knie has served as President and Chief Executive Officer and as a director of the Company since May 2017. Mr. Knie served as the President of Lifeline Industries Inc. since its inception in 1995. From 2002 to 2010 he was a Semiconductor Analyst for PAW Partners. From 1993 until 1995, Mr. Knie served as Northeast Regional Manager of American Express Financial Advisors.
Mr. Knie has served as a board member for NASDAQ-listed companies. He has been featured on CNBC, Bloomberg, The Wall Street Journal and Forbes Magazine as an Independent Equity Analyst. Mr. Knie has over 20 years of equity markets experience. Mr. Knie has been a member of the American Chemical Society, Institute of Electrical and Electronics Engineers, as well as The National Alliance for Youth Sports.
Stefanie Johns, Ph.D.
Chief Scientific Officer
Stefanie joined Hoth Therapeutics full time in September 2020. Prior to joining Hoth, Stefanie served as Director of Regulatory Affairs at Enable Injections, Inc., where she led the global regulatory strategy for the subcutaneous drug delivery device platforms. As a consultant at Camargo Pharmaceutical Services, Stefanie provided strategic regulatory and development guidance on over 30 505(b)(2) drug and drug-device combination product programs spanning the Dermatology, Cardiovascular and Renal, Gastroenterology, Pulmonary, Neurology, Oncology, Anesthesiology/Pain, Psychiatry, Urology/Gynecology, and Rare Disease Divisions at FDA. Stefanie was also a contributing scientist in the development of the Hoth BioLexa Platform technology, scheduled to enter clinical trials in Q4 2020, and has served on the Hoth Scientific Advisory Board since March 2019, providing strategic regulatory guidance across the pipeline portfolio. Stefanie received her Ph.D. in protein biochemistry from the University of Cincinnati and a B.S. in Biological Sciences from Wright State University.
Chief Financial Officer
David S. Briones is the founder and managing member of the Brio Financial with over fifteen years of public accounting and executive level experience. He consults with various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. David has developed a specialty representing private companies as the outsourced CFO/Financial reporting specialist as a private company navigates toward becoming a public company through a self-filing, a reverse merger or through a traditional initial public offering. David’s client list crosses various industries: Technology/Internet, Manufacturing, Oil and Gas, Food and Beverage, Bio-technology, Software, Medical Device, Entertainment, Hedge Funds and Insurance. Prior to founding Brio, Mr. Briones had managed the Public Company and Hedge Fund practices at Bartolomei Pucciarelli, LLC (“BP”). Within that capacity, he performed audit services, outsourced CFO functions, and/or consulted with clients through difficult SEC comment periods particularly through application of complex accounting principles for a vast public company client base. Prior to joining BP, Mr. Briones was an auditor with PricewaterhouseCoopers LLP in New York, New York. He specialized in the financial services group, and most notably worked the MONY Group, Prudential Financial, and MetLife initial public offerings. He was promoted to Sr Associate after only 8 months of service at PwC and acted in managerial roles within his first two years at PwC.
VP of Operations
Hayley joined the Hoth Therapeutics team in December 2017 as Vice President of Operations. She has more than 6 years in operational management experience. Prior to joining Hoth, Hayley worked in various office, executive and administrative positions over the past 15 years. Hayley received her Bachelors of Science from Brigham Young University and received a Continuing Education Certificate in Accounting from NYU as well as completed Rutgers Business School’s Mini-MBA program in BioPharma Innovation.
JONATHAN HALE ZIPPIN M.D., Ph.D.
Senior Scientific Advisor
Jonathan Zippin MD, PhD attended Cornell University where he received a Bachelor’s of Science with Honors. He then attended the Rockefeller/Cornell/Sloan-Kettering Tri-Institutional MD/PhD program. He completed his general medicine internship at the Mount Sinai Hospital in New York City, followed by a residency in dermatology at the Weill Cornell Medical Center – New York Presbyterian Hospital. Dr. Zippin is an Associate Attending Dermatologist and Associate Professor of Dermatology and Pharmacology at Weill Medical College of Cornell, and is the Vice Chair of Research for the Department of Dermatology. For the past 18 years, he has helped to establish the role of distinct cAMP microdomains in mammalian cell biology and revealed new mechanisms in insulin release and cancer. For the past ten years, Dr. Zippin’s laboratory has been dedicated to understanding the role of cAMP microdomains in skin disease. Dr. Zippin has served as a consultant for numerous pharmaceutical companies including Pfizer and Cellgene. He is also the founder of a biotechnology company that is developing antibody based diagnostics for cancer. Dr. Zippin has published numerous peer-reviewed papers and book chapters and serves on the board of multiple scientific societies.
Hoth Therapeutics seeks to enhance shareholder value not only through business performance and practices, but also through responsible and effective communication with its shareholders.